医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ACRO Testifies Before U.S. International Trade Commission On Effects of India Industrial Policies on Economy

2014年02月19日 AM01:10
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

ACRO's John Lewis preparing to testify before U.S. International Trade Commission (Photo: Business Wire) ACRO’s John Lewis preparing to testify before U.S. International Trade Commission (Photo: Business Wire)

View and Share Photo

Close Window


WASHINGTON

Members of the Association of Clinical Research Organizations (ACRO) have seen their clinical trials activity in India decrease more than 60 percent since 2010 as a result of a “confusing, inconsistent and arbitrary” regulatory environment, ACRO’s Vice President of Public Affairs, John Lewis, testified before the United States International Trade Commission. The USITC hearing was held last week in Washington, DC.

ACRO's John Lewis preparing to testify before U.S. International Trade Commission (Photo: Business W ...

ACRO’s John Lewis preparing to testify before U.S. International Trade Commission (Photo: Business Wire)

“To be clear, ACRO members are committed to conducting safe, ethical, high-quality clinical research across the globe. But to do that, researchers and research companies must depend upon a regulatory framework that is reasonable and rooted in science, not politics,” Lewis testified.

ACRO members have been operating in India since 1999 and have invested more than $100 million in the country building out a research infrastructure, training thousands of employees and establishing approximately two dozen facilities around the country. ACRO member companies have conducted an estimated two-thirds of all industry-sponsored clinical trials in India. In 2010, there were 256 industry-sponsored trials being conducted in India, according to clinicaltrials.gov, but this number fell to 86 by last year.

“In reality, research can be relocated to more hospitable countries to mitigate the direct economic damage,” Lewis continued. “The real loss is to the global research environment that is critical to the efficient development of new treatments and therapies for patients in need, in the U.S., in India and around the world.”

About ACRO

The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics and medical devices. The association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 100,000 professionals worldwide and annually conduct more than 11,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140218006290/en/

CONTACT

Association of Clinical Research Organizations (ACRO)
John
Lewis, 202-464-9340

jlewis@acrohealth.org

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent